Sequence and structure analysis

3D structure model building of potential antibody-antigen interactions Surface hydrophobicity and charge profiling CDRs lengths analysis (TAP) and comparison against CST Sequence liabilities identification (oxidation, deamidation, isomerisation, glycosylation and fragmentation) and risk assessment Structural liabilities identification (regions prone to misfolding) and risk assesment Solubility and aggregation analysis: identification of hydrophobic sequences and patches

Sequence design of variants

Sequence design of variants to eliminate all developability risks, improve manufacturability, stability, solubility, aggregation tendency, and expression yield, while maintaining the highest possible initial parameters, such as degree of humanization, target specificity, and affinity.

GO / NO-GO checkpoint

The customer chooses the variants to be expressed and tested, according to detailed data and our experts’ advise.

High-throughput transient recombinant IgG expression & purification

The selected sequences are expressed using our proprietary platform, for optimal performance.

Tests of binding & physicochemical properties

Verification that the variants designed & expressed in previous steps exhibit reduced liabilities and enhanced developability while preserving antigen-binding capability.

Which parameters are evaluated (PTMs, charge distribution, viscosity risk, immunogenicity, manufacturability)?

PTMs / chemical liabilities: oxidation, deamidation, isomerisation, glycosylation, fragmentation (with risk assessment). Charge distribution: surface charge profiling. Hydrophobicity / aggregation / solubility: surface hydrophobicity profiling, hydrophobic sequences/patches, solubility & aggregation analysis. Structural liabilities: regions prone to misfolding (with risk assessment). Immunogenicity: in silico prediction of HLA-DR/DQ/DP binding scores, T-cell epitope mapping, germline comparison, and substitution heatmaps. Manufacturability: explicitly targeted in the optimization goals (improve manufacturability, stability, solubility, aggregation tendency, expression yield).

Does your AI propose specific mutations to improve stability, solubility, or expression levels?

Yes. The service includes sequence design of variants to eliminate developability risks and improve stability, solubility, aggregation tendency, manufacturability, and expression yield.For immunogenicity, it also provides heatmaps of the effect of all possible substitutions in potentially immunogenic regions and highlights potentially favorable mutations.

Can you optimize without sacrificing affinity or specificity?

The optimization is performed while maintaining the highest possible initial parameters, including target specificity and affinity. Affinity and binding are checked experimentally after production by ELISA and SPR/BLI KD.

Is it possible to target multiple properties at once (e.g., reduce aggregation while increasing thermostability)?

Our AI-driven developability service addresses all developability risks and improves multiple properties (e.g., aggregation tendency, stability, solubility, manufacturability, expression yield) in the same design effort, with experimental testing that includes aggregation readouts (SEC-HPLC, DLS) and thermostability (nanoDSF).

What is the typical timeline for sequence assessment and optimized variant generation?

This service usually takes about 3-4 weeks.

Does the workflow include experimental validation (expression, aggregation assays, thermal shift)?

Yes. It includes: High-throughput transient recombinant IgG expression & purification (MAX platform, XtenCHO-Race cells). Stress testing under multiple conditions and analytical methods including SEC-HPLC & DLS (aggregation/size) and nanoDSF (thermostability), plus ELISA and SPR/BLI (KD).

Is your process compatible with antibodies from various platforms (phage display, hybridoma, single B cell, synthetic libraries)?

Yes. The process is compatible with antibodies generated from all major discovery platforms, including phage display, hybridoma, and single B cell.

Do I retain complete ownership of optimized sequences and generated data?

The intellectual property of AI-generated variant (mutated) sequences fully belongs to the customer, with no extra royalty nor milestone payments.

Are there licensing fees or restrictions on the AI-generated variants?

There are no IP restrictions or licensing fees. ProteoGenix does not demand extra royalty nor milestone payments.

Do you offer integrated services covering affinity maturation, humanization, expression, and characterization?

Yes. The developability/liability workflow can be coupled with ProteoGenix services such as humanization, engineering, affinity maturation, and cell line development (CLD). The service also includes expression, purification, and in-depth characterization of selected variants (binding, affinity/KD, thermostability, aggregation, etc.).

Can you support large antibody portfolios requiring high-throughput developability screening?

Yes, we can support your project no matter the size thanks to our proprietary high-throughput platform.

AI-driven antibody developability assessment service

Maximize your chances of getting to the clinic

AI/wet-lab expertise

3-4 weeks

Reduce costs

Maximize chances of success

3D modeling

Proprietary AI made with 10B sequences

More Than AI: Expert Guidance Behind Every Recommendation

ProteoGenix’s Proprietary AI

Built on a dataset of ~10 billion sequences and continuously strengthened by ProteoGenix’s own complex antibody projects, our proprietary AI helps you make better decisions from the earliest design stage. By combining large-scale sequence analysis with real-world project learnings, it supports the selection of human frameworks and the prioritization of variants with stronger developability profiles, so you can move forward with an optimized antibody that preserves binding and function while reducing downstream risk.

Talk with our Experts

Expert Guidance

Our bioinformatics experts review every AI output and translate it into clear, experience-driven recommendations before you move into production. They check the proposed frameworks and mutations, weigh trade-offs between “humanness,” liability risk and sequence integrity. The result is not just a list of candidates, but a practical decision package that helps you choose the best formats, backed by both data and expert judgment.

Discuss your Project with us

Save Time and Resources: Spot Developability Risks Early to Protect your Clinical Success

We stress-test your antibody variants under manufacturing, storage, and handling conditions to spot early weaknesses that could derail clinical development. We deliver a clear actionable report based on a combination of stress studies with analytical assays for integrity, binding, aggregation, affinity et cetera… Then, our expert recommendations help you select the most robust candidates and choose your next step.

See How we can Improve your Antibody

AI antibody developability assessment guided by the critical eye of our bioinformatics experts

- 3D structure model building of potential antibody-antigen interactions
- Surface hydrophobicity and charge profiling
- CDRs lengths analysis (TAP) and comparison against CST
- Sequence liabilities identification (oxidation, deamidation, isomerisation, glycosylation and fragmentation) and risk assessment
- Structural liabilities identification (regions prone to misfolding) and risk assesment
- Solubility and aggregation analysis: identification of hydrophobic sequences and patches
Sequence design of variants to eliminate all developability risks, improve manufacturability, stability, solubility, aggregation tendency, and expression yield, while maintaining the highest possible initial parameters, such as degree of humanization, target specificity, and affinity.

Spot Your Antibody’s weaknesses

One single partner for your entire project with our integrated services

Custom antibody development from discovery to large scale production

Antibody Discovery

Antibody Affinity Maturation

Antibody humanization

Antibody Engineering

Recombinant Antibody Production

Stable Cell Line Development

Save time and resources with our AI-driven antibody services

AI-boosted Affinity Maturation

AI-powered Humanization

AI-driven Epitope & Paratope Mapping

FAQ

- PTMs / chemical liabilities: oxidation, deamidation, isomerisation, glycosylation, fragmentation (with risk assessment).
- Charge distribution: surface charge profiling.
- Hydrophobicity / aggregation / solubility: surface hydrophobicity profiling, hydrophobic sequences/patches, solubility & aggregation analysis.
- Structural liabilities: regions prone to misfolding (with risk assessment).
- Immunogenicity: in silico prediction of HLA-DR/DQ/DP binding scores, T-cell epitope mapping, germline comparison, and substitution heatmaps.
- Manufacturability: explicitly targeted in the optimization goals (improve manufacturability, stability, solubility, aggregation tendency, expression yield).
Yes. The service includes sequence design of variants to eliminate developability risks and improve stability, solubility, aggregation tendency, manufacturability, and expression yield.
For immunogenicity, it also provides heatmaps of the effect of all possible substitutions in potentially immunogenic regions and highlights potentially favorable mutations.
Our AI-driven developability service addresses all developability risks and improves multiple properties (e.g., aggregation tendency, stability, solubility, manufacturability, expression yield) in the same design effort, with experimental testing that includes aggregation readouts (SEC-HPLC, DLS) and thermostability (nanoDSF).
Yes. It includes:
- High-throughput transient recombinant IgG expression & purification (MAX platform, XtenCHO-Race cells).
- Stress testing under multiple conditions and analytical methods including SEC-HPLC & DLS (aggregation/size) and nanoDSF (thermostability), plus ELISA and SPR/BLI (KD).
Yes. The developability/liability workflow can be coupled with ProteoGenix services such as humanization, engineering, affinity maturation, and cell line development (CLD). The service also includes expression, purification, and in-depth characterization of selected variants (binding, affinity/KD, thermostability, aggregation, etc.).

📢 -40% on Recombinant Antibody Production. Available until January 31, 2026 on your first order. Code: RECAB40

AI-driven antibody developability assessment service